| Id: | acc4557 |
| Group: | 1sens |
| Protein: | JNK |
| Gene Symbol: | MAPK8 |
| Protein Id: | P45983 |
| Protein Name: | MK08_HUMAN |
| PTM: | phosphorylation |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Immune system diseases |
| Disease: | Atopic Dermatitis |
| Disease Subtype: | |
| Disease Cellline: | HMC-1 |
| Disease Info: | |
| Drug: | JC3 |
| Drug Info: | JC3 is a drug with its specific characteristics and functions in the medical field. |
| Effect: | modulate |
| Effect Info: | "JC3 treatment can significantly reduce the phosphorylation level of MAPK in PMA-stimulated HMC-1 cells, indicating that it alleviates AD-related inflammation by inhibiting the MAPK signaling pathway." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 30729380 |
| Sentence Index: | 30729380_8 |
| Sentence: | "Moreover, treatment with JC3 (10 mg/kg) significantly decreased serum and ear tissues levels of IFN-gamma and IL-4 in AD mice." |
Sequence & Structure:
MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAAGPLGCCR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MAPK8 | BENTAMAPIMOD | c-Jun N-terminal kinase, JNK inhibitor | 2 | Completed | endometriosis | ClinicalTrials |
| MAPK8 | TANZISERTIB | c-Jun N-terminal kinase 1 inhibitor | 2 | Terminated | idiopathic pulmonary fibrosis | ClinicalTrials |
| MAPK8 | TANZISERTIB | c-Jun N-terminal kinase 1 inhibitor | 2 | Terminated | lupus erythematosus | ClinicalTrials |
| MAPK8 | CC-401 | c-Jun N-terminal kinase 1 inhibitor | 1 | Terminated | myeloid leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MAPK8-Ser301 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8-Thr183 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8-Tyr185 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP2-Ser250 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP2-Ser251 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP2-Ser254 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP3-Ser207 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | -0.707 | ||||
| UCEC | |||||
| MAPK8IP3-Ser365 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.014 | ||||
| HGSC | -1.48 | ||||
| ccRCC | -0.292 | ||||
| GBM | -0.5 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 1.549 | ||||
| non_ccRCC | |||||
| PDAC | -0.198 | ||||
| UCEC | -0.092 | ||||
| MAPK8IP3-Ser579 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.237 | ||||
| HGSC | 0.319 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -1.233 | ||||
| LUSC | |||||
| non_ccRCC | 1.15 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP3-Ser596 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 0.707 | ||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP3-Ser670 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.002 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -0.998 | ||||
| HNSC | |||||
| LUAD | -0.004 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MAPK8IP3-Thr275 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.746 |
| HGSC | -1.136 |
| ccRCC | |
| GBM | 0.39 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | U | Osteogenic sarcoma/osteosarcoma | Phosphorylation | 24025361 |
| - | - | U | Alzheimer's disease | Phosphorylation | 24405770 |
| - | - | U | Parkinson's disease | Phosphorylation | 24405770 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
